CELUW supply chain intelligence for Celularity Inc: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Celularity Inc (CELUW) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ADAPY | ADAPY | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| ADAPY | ADAPY | 72% | Reciprocal relationship from ADAPY graph: Reciprocal relationship from CELUW graph: Reciprocal relationship from ADAPY graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our int… |
| ALLO | Allogene Therapeutics, Inc. | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from CELUW graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our inten… |
| ATRA | Atara Biotherapeutics, Inc. | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| ATRA | Atara Biotherapeutics, Inc. | 72% | Reciprocal relationship from ATRA graph: Reciprocal relationship from CELUW graph: Reciprocal relationship from ATRA graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our inten… |
| DTIL | Precision BioSciences, Inc. | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from CELUW graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our inten… |
| IPSC | Century Therapeutics, Inc. | 72% | Reciprocal relationship from IPSC graph: Reciprocal relationship from CELUW graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our inten… |
| IPSC | Century Therapeutics, Inc. | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from CELUW graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our inten… |
| NTLA | Intellia Therapeutics, Inc. | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| ORGO | Organogenesis Holdings Inc. | 72% | Reciprocal relationship from ORGO graph: Reciprocal relationship from CELUW graph: Reciprocal relationship from ORGO graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our inten… |
| ORGO | Organogenesis Holdings Inc. | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allog… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ADAPY | ADAPY | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| ADAPY | ADAPY | 72% | Reciprocal relationship from ADAPY graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allo… |
| ALLO | Allogene Therapeutics, Inc. | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allog… |
| ATRA | Atara Biotherapeutics, Inc. | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| ATRA | Atara Biotherapeutics, Inc. | 72% | Reciprocal relationship from ATRA graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allog… |
| DTIL | Precision BioSciences, Inc. | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allog… |
| IPSC | Century Therapeutics, Inc. | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| IPSC | Century Therapeutics, Inc. | 72% | Reciprocal relationship from IPSC graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allog… |
| NTLA | Intellia Therapeutics, Inc. | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allog… |
| ORGO | Organogenesis Holdings Inc. | 72% | Reciprocal relationship from ORGO graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allog… |
| ORGO | Organogenesis Holdings Inc. | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from CELUW graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from CELUW graph: . Our pipeline reflects our inten… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CELUW-DEBT-8584 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2024-12-31. |
| CELUW-DEBT-8583 | Warrants outstanding: 892856 | 90% | xbrl warrant detail from xbrl 2024-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DTIL | Precision BioSciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| IPSC | Century Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ADAPY | Adaptimmune Therapeutics PLC | 100.00 | 1 | ['customer', 'supplier'] |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ORGO | Organogenesis Holdings Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| SGMO | Sangamo Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| NTLA | Intellia Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BMYMP | Bristol-Myers Squibb Co | 50.00 | 2 | |
| BMY | Bristol-Myers Squibb Company | 50.00 | 2 | |
| AZN | AstraZeneca PLC | 50.00 | 2 | |
| CELU | Celularity Inc. | 50.00 | 2 | |
| CLLS | Cellectis S.A. | 50.00 | 2 | |
| GDTC | CytoMed Therapeutics Limited | 50.00 | 2 | |
| ARTV | Artiva Biotherapeutics, Inc. | 50.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 50.00 | 2 | |
| SI | Shoulder Innovations, Inc. | 50.00 | 2 | |
| FISI | Financial Institutions, Inc. | 50.00 | 2 | |
| TGTX | TG Therapeutics, Inc. | 50.00 | 2 | |
| INAB | IN8bio, Inc. | 50.00 | 2 |